Financhill
Back

Altimmune Quote, Financials, Valuation and Earnings

Altimmune Price Quote

$7.74
+0.31 (+4.17%)
(Updated: September 19, 2024 at 12:30 PM ET)

Altimmune Key Stats

Buy
54
Altimmune (ALT) is a Buy

Day range:
$7.20 - $7.87
52-week range:
$2.09 - $14.84
Dividend yield:
0%
P/E ratio:
0.00
P/S ratio:
1,152.92
P/B ratio:
3.46%

Volume:
2.2M
Avg. volume:
2.4M
1-year change:
174.17%
Market cap:
$528.1M
Revenue:
$426K
EPS:
$-1.64

How Much Does Altimmune Make?

  • How Much Are Altimmune's Sales Annually?
    ALT Revenues are $426K
  • How Much Profit Does Altimmune's Make A Year?
    ALT net income is -$88.4M

Is Altimmune Growing As A Company?

  • What Is Altimmune's Growth Rate Quarterly?
    Quarterly YoY revenue growth is -0.17%
  • What Is Altimmune's EPS Quarterly YoY Growth Rate?
    Quarterly, year-over-year diluted EPS growth rate is 0%

Altimmune Stock Price Performance

  • Did Altimmune Stock Go Up Last Month?
    Altimmune share price went up by 14.48% last month
  • Did ALT's Share Price Rise Over The Last Year?
    ALT share price rose by 174.17% over the past 1 year

What Is Altimmune 52-Week High & Low?

  • What Is Altimmune’s 52-Week High Share Price?
    Altimmune has traded as high as $14.84 over the past 52 weeks
  • What Is Altimmune’s 52-Week Low Share Price?
    Altimmune has traded as low as $2.09 over the past 52 weeks

Altimmune Price To Free Cash Flow

Data Unavailable

Is It Risky To Buy Altimmune?

  • How Much Debt Does Altimmune Have?
    Total long term debt quarterly is $0
  • How Much Cash Does Altimmune Have?
    Cash and short term investments quarterly total is $164.9M
  • What Is Altimmune’s Book Value Per Share?
    Book value per share is 2.15

Is Altimmune Cash Flow Positive?

  • What Is ALT Cash Flow From Operations?
    Cash flow from operations (TTM) is -$71.5M
  • What Is Altimmune’s Cash Flow From Financing?
    Cash flow from financing (TTM) is $73M
  • What Is Altimmune’s Cash Flow From Investing?
    Cash flow from investing (TTM) is -$46.8M

Altimmune Return On Invested Capital

  • Is Management Doing A Good Job?
    ALT return on invested capital is -60.49%
  • What Is Altimmune Return On Assets?
    ROA measures how assets are converting to revenues and is -54.95%
  • What Is ALT Return On Equity?
    ROE is a measure of profitability and is -60.49%

Altimmune Earnings Date & Stock Price

  • What Is Altimmune's Stock Price Today?
    A single share of ALT can be purchased today for 7.43
  • What Is Altimmune’s Stock Symbol?
    Altimmune trades on the nasdaq under the ticker symbol: ALT
  • When Is Altimmune’s Next Earnings Date?
    The next quarterly earnings date for Altimmune is scheduled on November 7, 2024
  • When Is ALT's next ex-dividend date?
    Altimmune's next ex-dividend date is January 20, 2017
  • How To Buy Altimmune Stock?
    You can buy Altimmune shares by opening an account at a top tier brokerage firm, such as TD Ameritrade or tastyworks.

Altimmune Competitors

  • Who Are Altimmune's Competitors?
    Below is a list of companies who compete with Altimmune or are related in some way:
    • Amgen Inc (AMGN)
    • Eli Lilly and Co (LLY)
    • Inari Medical Inc (NARI)
    • Pfizer Inc (PFE)
    • Viking Therapeutics Inc (VKTX)

Altimmune Dividend Yield

  • What Is ALT Dividend Yield?
    Altimmune’s dividend yield currently is 0%
  • What Is Altimmune’s Payout Ratio?
    Altimmune’s payout ratio is 0%
  • When Did Altimmune Last Pay A Dividend?
    The latest dividend pay date is September 19, 2024
  • What Is Altimmune’s Dividend Per Share?
    Altimmune pays a dividend of $0.00 per share

Altimmune Analyst Estimates

YoY Growth Past Surprise
EPS: 0% -1.45%
Revenue: -16.67% 706.45%

Analyst Recommendations

Buy Recommendations: 3
Hold Recommendations: 1
Sell Recommendations: 0
Price Target: 20.57
Upside from Last Price: 176.87%

Major Shareholders

  • How many ALT shares are owned by institutional investors?
    68.9M ALT shares are owned by institutional investors
  • How many ALT shares are owned by insiders?
    5.2M ALT shares are owned by insiders